Seikagaku News

Ferring Announces U.S. FDA Advisory Committee Meeting for SI-6603 (Condoliase), An Investigational Treatment in Lumbar Disc Herniation

BusinesswireDec 2, 2024 09:05 ET

Seikagaku Corp Sees FY Net Y3.45B

Dow JonesNov 10, 2024 23:00 ET

Ferring Presents Efficacy and Safety Data From Two Phase 3 Studies for Investigational Treatment, SI-6603 (Condoliase), in Lumbar Disc Herniation at NASS 2024

BusinesswireSep 25, 2024 08:00 ET

Seikagaku Corp 1Q Net Y1.90B Vs Net Y1.89B

Dow JonesAug 5, 2024 02:30 ET

Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (Condoliase), in Lumbar Disc Herniation at ASPN 2024

BusinesswireJul 15, 2024 08:00 ET

Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation

BusinesswireJun 24, 2024 08:00 ET

Seikagaku Corp FY Net Y2.19B Vs Net Y2.24B

Dow JonesMay 13, 2024 03:00 ET

Seikagaku Corp 9-Mos Net Y2.70B Vs Net Y3.63B

Dow JonesFeb 13, 2024 21:30 ET

Seikagaku Corp 1H Net Y2.10B Vs Net Y3.14B

Dow JonesNov 8, 2023 02:00 ET

Seikagaku Corp Sees FY Net Y1.45B

Dow JonesAug 4, 2023 02:01 ET

Seikagaku Corp FY Net Y2.24B Vs Net Y3.73B

Dow JonesMay 12, 2023 03:01 ET

Seikagaku Corp Sees FY Net Y2.65B

Dow JonesFeb 8, 2023 01:05 ET

Seikagaku Corp 1H Net Y3.14B Vs Net Y5.02B

Dow JonesNov 8, 2022 02:02 ET

Seikagaku Corp Raises FY Dividend Plan to Y26.00

Dow JonesNov 8, 2022 02:01 ET